Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia
Copyright © 2020 Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Several studies have reported the beneficial effect of glucocorticoids in the treatment of cytokine storm that occurs in patients with severe COVID-19. Various glucocorticoids regimens have been proposed.
METHODS: Retrospective observational study that includes patients with severe SARS-CoV-2 pneumonia and compares admission to an Intensive Care Unit (ICU) or death during hospitalization in three groups of patients: no glucocorticoids treatment, use of glucocorticoids doses equivalent to less than 250mg of prednisone daily and use of equivalent doses greater than or equal to 250mg of prednisone daily. Multivariate analysis was performed using logistic regression, using the propensity index as a covariant.
RESULTS: Of the 259 patients enrolled in the study, 67 (25.9%) had an unfavorable evolution, dying or requiring ICU admission. Comparative analyzes between different glucocorticoids treatments and the association with ICU admission or death were: glucocorticoids treatment (any dose) versus no glucocorticoids treatment (OR: 0.71 [0.30-1.66]), treatment with glucocorticoids (≥250mg prednisone daily) versus no glucocorticoids treatment (OR: 0.35 [0.11-1.08]) and glucocorticoids treatment (≥250mg prednisone daily) versus patients with glucocorticoids doses <250mg prednisone daily or without glucocorticoids treatment (OR: 0.30 [0.10-0.88]).
CONCLUSION: The results of this study show that patients with severe SARS-CoV-2 pneumonia treated with glucocorticoids pulses with equivalent doses of prednisone greater than or equal to 250mg have a more favorable evolution (less mortality and less admission to ICU).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Medicina clinica - 156(2021), 5 vom: 12. März, Seite 221-228 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Pascual Pareja, José Francisco [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.03.2021 Date Revised 10.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2020.11.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319444457 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319444457 | ||
| 003 | DE-627 | ||
| 005 | 20231225171446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2020.11.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319444457 | ||
| 035 | |a (NLM)33380371 | ||
| 035 | |a (PII)S0025-7753(20)30820-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pascual Pareja, José Francisco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia |
| 246 | 3 | 3 | |a Efectividad de los glucocorticoides en pacientes hospitalizados por neumonía grave por SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.03.2021 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Several studies have reported the beneficial effect of glucocorticoids in the treatment of cytokine storm that occurs in patients with severe COVID-19. Various glucocorticoids regimens have been proposed | ||
| 520 | |a METHODS: Retrospective observational study that includes patients with severe SARS-CoV-2 pneumonia and compares admission to an Intensive Care Unit (ICU) or death during hospitalization in three groups of patients: no glucocorticoids treatment, use of glucocorticoids doses equivalent to less than 250mg of prednisone daily and use of equivalent doses greater than or equal to 250mg of prednisone daily. Multivariate analysis was performed using logistic regression, using the propensity index as a covariant | ||
| 520 | |a RESULTS: Of the 259 patients enrolled in the study, 67 (25.9%) had an unfavorable evolution, dying or requiring ICU admission. Comparative analyzes between different glucocorticoids treatments and the association with ICU admission or death were: glucocorticoids treatment (any dose) versus no glucocorticoids treatment (OR: 0.71 [0.30-1.66]), treatment with glucocorticoids (≥250mg prednisone daily) versus no glucocorticoids treatment (OR: 0.35 [0.11-1.08]) and glucocorticoids treatment (≥250mg prednisone daily) versus patients with glucocorticoids doses <250mg prednisone daily or without glucocorticoids treatment (OR: 0.30 [0.10-0.88]) | ||
| 520 | |a CONCLUSION: The results of this study show that patients with severe SARS-CoV-2 pneumonia treated with glucocorticoids pulses with equivalent doses of prednisone greater than or equal to 250mg have a more favorable evolution (less mortality and less admission to ICU) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Coronavirus infection disease 2019 (COVID-19) | |
| 650 | 4 | |a Corticoides | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Enfermedad por coronavirus 2019 (COVID-19) | |
| 650 | 4 | |a Propensity index | |
| 650 | 4 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a Síndrome agudo respiratorio severo por coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a Índice de propensión | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a García-Caballero, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Soler Rangel, Llanos |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez-Ronda, Miguel Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Roa Franco, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro Jiménez, Gema |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno Palanco, Miguel Angel |e verfasserin |4 aut | |
| 700 | 1 | |a González-Ruano, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a López-Menchaca, Ramiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ruíz-Seco, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Pagán Muñoz, Bárbara |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Gómez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Monte, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Fuerte Martínez, Rebeca |e verfasserin |4 aut | |
| 700 | 1 | |a Valle López, Jose Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz Blanco, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Rábago Lorite, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Martín, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Serralta San Martín, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Cerezo, Jorge Francisco |e verfasserin |4 aut | |
| 700 | 0 | |a en nombre del grupo de trabajo HUIS-COVID-19 |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 156(2021), 5 vom: 12. März, Seite 221-228 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2021 |g number:5 |g day:12 |g month:03 |g pages:221-228 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2020.11.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2021 |e 5 |b 12 |c 03 |h 221-228 | ||